Huvepharma has acquired the global rights for the full OptiPhos, brand, product and registrations from Enzyvia.
OptiPhos is an E. coli 6-phytase, first marketed in 2006 in the United States and now sold in 47 countries around the world. The addition of the global rights of OptiPhos is an excellent extension to Huvepharma’s existing enzyme business. Huvepharma has previously marketed and distributed OptiPhos as a partner of Enzyvia for different countries in the Middle East, Europe, Africa and Asia.
Along with the OptiPhos brand, all related patents, intellectual property, trademarks, global regulatory registrations, and production assets are included in this transaction. This acquisition gives Huvepharma a global position with the Optiphos current product range, concentrations, and services offered now for OptiPhos by Enzyvia. This will be continued by Huvepharma during the transition and beyond.
To comment, login here
Or register to be able to comment.